Ben Orsburn received his Ph.D. from Virginia Tech for using mass spectrometry to study the cell walls of bacterial pathogens. He performed two postdoctoral fellowships, at the Johns Hopkins University and the National Cancer Institute, respectively where he expanded his skills toward the transcriptomics and proteomics of cancer.
After extensive trainings in mass spectrometry and proteomics, he spent 8 years traveling the globe as a senior field applications scientist in proteomics for Thermo Fisher Scientific. To date, he has helped to develop advanced applications in proteomics and metabolomics in over 160 labs around the world.
He is the founder of News in Proteomics Research, the highest frequently visited mass spectrometry and proteomics blog on the internet, dedicated to breaking down today’s most relevant advances in the field in the most approachable format possible. He is a contributing author of over 40 scientific articles and editorials, as well as three books on mass spectrometry. In 2018 he founded LCMSMethods.org, a site dedicated to improving proteomics and mass spectrometry through the release of instrument methods curated by subject matter experts. For this work he was awarded a position on the Workflow Interest Network of the Association of Biomedical Research Facilities. His research has been featured in Science Daily, GenomeWeb and other media outlets. In March of 2020 his work on accelerating the development of COVID diagnostic assays received mainstream media attention.
Today, he has returned to Johns Hopkins as a faculty member in the Department of Pharmacology and Molecular Sciences. His research is focused on the application of proteomics and single-cell proteomics toward more comprehensive understanding of drug activity and toxicity.
